HEART AND LUNG THERAPIES
At Xenios, a Fresenius Medical Care company, we offer treatments for patients suffering from cardiac and/or pulmonary failure. Based on a holistic understanding of human physiology, we develop intelligent technological solutions that can be vital for the survival of critically ill patients.
We offer solutions that combine both cardiac and pulmonary support on one single technological platform. It supports the gas exchange in the lungs and the cardiovascular system to keep patients alive. The physician thus gains more vital treatment time during diagnosis and therapy.
Xenios is part of Fresenius Medical Care, the world’s leading provider of products and services for people with renal diseases. We are complementing Fresenius Medical Care’s product portfolio in the field of intensive care and are continuing to shape the future of extracorporeal multi-organ support.
In our daily work, we share a passion for helping people. For patients. Worldwide. Every day.
Medos is your partner experienced in cardiopulmonary solutions for more than 30 years: highly skilled employees and high-quality manufacturing, for the benefit of cardiac surgeons, perfusionists and patients.
SYNCHRONIZED CARDIAC SUPPORT
Synchronized Cardiac Support is a new mechanical circulatory support method that adapts to the patient’s heart rhythm.
Pulsatility is closer to human physiology than continuous flow. The therapeutic goals are myocardial recovery and adequate organ perfusion.
Novalung therapy allows to mitigate, prevent or replace mechanical ventilation by extracorporeal gas exchange. It enables caregivers to give the lung time to heal and change the therapy environment in the ICU – from CO2 removal to full oxygenation.
Our international clinical support team accompanies the clinical application of all Fresenius Medical Care Heart & Lung products.
These specialists, trained in intensive care, provide trainings on-site in hospitals or online, e.g. for initial applications of our products.
HEART & LUNG CAMPUS
LEARNING WITH XENIOS
LOOKING FOR FURTHER THERAPY- AND XENIOS PRODUCT INFORMATION?
Join our Heart & Lung Campus to explore various eLearnings, for example expert interviews, best-practice-cases, medical knowledge, hands-on-tutorials and priming instructions.
On demand, 24 hours a day, 7 days a week – whenever you need it.
Merger: Medos becomes fully integrated within Xenios
Medos Medizintechnik AG was merged into Xenios AG. This streamlines processes within the company and at the same time it grows closer to the parent company Fresenius Medical Care AG & Co. KGaA. Medos Medizintechnik AG (Medos) was founded in 1987 with a focus on cardiopulmonary solutions. Together with ...
Xenios AG receives approval in China for ECMO devices
Xenios AG, a Fresenius Medical Care company, has received approval from the National Medical Products Administration (NMPA) in China for the Xenios console and patient kits for ECMO therapy. In early May, Xenios AG, a Fresenius Medical Care company, received approval for two patient kits in China. It follows NMPA’s ...
EuroELSO 2021 Virtual Congress
Meet Fresenius Medical Care Heart & Lung (Xenios) at EuroELSO 2021 and join our symposium! In our virtual ICU, you will learn about our products and therapies directly on a VV ECMO patient case. Talk to our experts via text chat and ask all your questions. Also, join us for our ...
22. – 26. October
ESICM LIVES 2022
35th ESICM's (European Society Of Intensive Care Medicine) annual congress - LIVES
Queen Elizabeth II Congress Centre, London, England